Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind trial of freeze-dried Hib conjugate vaccine in healthy participants aged 2 months to 55 years
CTR20261511Phase 3Active
- Sponsor
- Lanzhou Institute of Biological Products Co., Ltd.
- Start
- May 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of Haemophilus b conjugate vaccine in Haemophilus influenzae type b invasive infection (Hib), sponsored by Lanzhou Institute of Biological Products Co., Ltd.. Started May 2026; status: active.
02
Drugs
Haemophilus b conjugate vaccine
03
Conditions
Haemophilus influenzae type b invasive infection (Hib)
Beyond the preview
Go deeper on CTR20261511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261511.